<DOC>
	<DOC>NCT01744756</DOC>
	<brief_summary>A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.</brief_summary>
	<brief_title>Subconjunctival Bevacizumab and Recurrent Pterygium</brief_title>
	<detailed_description>1. Pacients with recurrent pterygium 2. Anti-VEGF therapy -Bevacizumab</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Recurrent pterygium Pregnant or lactating women History of myocardial infarction History of stroke</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Subconjunctival Bevacizumab</keyword>
	<keyword>Recurrent pterygium</keyword>
</DOC>